Compare Stocks: XLO, CGEN, WHWK, and TARA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.49	$2.45	$1.29 ▼ $3.23	$235.44M	2.78	237,499 shs	127,601 shs
TARA Protara Therapeutics	$3.55	$3.95	$3.11 ▼ $7.82	$209.79M	1.49	669,880 shs	3.95 million shs
WHWK Whitehawk Therapeutics	$4.20	$4.30	$1.82 ▼ $5.49	$239.44M	0.81	327,256 shs	1.97 million shs
XLO Xilio Therapeutics	$9.13	$9.03	$6.47 ▼ $12.74	$60.08M	-0.14	10,281 shs	22,937 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	0.00%	+0.81%	-4.96%	+20.29%	+87.22%
TARA Protara Therapeutics	0.00%	-7.07%	-7.79%	-13.63%	+11.29%
WHWK Whitehawk Therapeutics	0.00%	+2.19%	-11.21%	-5.83%	+118.75%
XLO Xilio Therapeutics	0.00%	+2.24%	-1.08%	+2.13%	-16.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.49	$2.45	$1.29 ▼ $3.23	$235.44M	2.78	237,499 shs	127,601 shs
TARA Protara Therapeutics	$3.55	$3.95	$3.11 ▼ $7.82	$209.79M	1.49	669,880 shs	3.95 million shs
WHWK Whitehawk Therapeutics	$4.20	$4.30	$1.82 ▼ $5.49	$239.44M	0.81	327,256 shs	1.97 million shs
XLO Xilio Therapeutics	$9.13	$9.03	$6.47 ▼ $12.74	$60.08M	-0.14	10,281 shs	22,937 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	0.00%	+0.81%	-4.96%	+20.29%	+87.22%
TARA Protara Therapeutics	0.00%	-7.07%	-7.79%	-13.63%	+11.29%
WHWK Whitehawk Therapeutics	0.00%	+2.19%	-11.21%	-5.83%	+118.75%
XLO Xilio Therapeutics	0.00%	+2.24%	-1.08%	+2.13%	-16.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$5.00	100.80% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	639.44% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	95.24% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XLO, CGEN, WHWK, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$74.00M	3.18	$0.37 per share	6.66	$1.09 per share	2.28
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A
WHWK Whitehawk Therapeutics	$7.14M	33.54	N/A	N/A	$2.89 per share	1.45
XLO Xilio Therapeutics	$43.77M	1.37	N/A	N/A	$7.31 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	$35.34M	$0.38	6.55	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest XLO, CGEN, WHWK, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.72	5.72
TARA Protara Therapeutics	N/A	10.97	10.97
WHWK Whitehawk Therapeutics	N/A	17.38	17.38
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
TARA Protara Therapeutics	38.13%
WHWK Whitehawk Therapeutics	52.08%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
TARA Protara Therapeutics	7.60%
WHWK Whitehawk Therapeutics	49.90%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	75	94.55 million	85.57 million	Optionable
TARA Protara Therapeutics	51	59.10 million	54.60 million	Optionable
WHWK Whitehawk Therapeutics	23	57.01 million	28.56 million	N/A
XLO Xilio Therapeutics	76	6.58 million	6.09 million	Not Optionable

XLO, CGEN, WHWK, and TARA Headlines

Recent News About These Companies

Reviewing Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL)

September 20 at 6:28 AM | americanbankingnews.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

August 28, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

April 1, 2026 | zacks.com

Xilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56

March 28, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, CGEN, WHWK, and TARA Company Descriptions

Compugen NASDAQ:CGEN

$2.49 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.48 -0.01 (-0.40%)

As of 08:31 AM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Protara Therapeutics NASDAQ:TARA

$3.55 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.59 +0.04 (+1.13%)

As of 08:57 AM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Whitehawk Therapeutics NASDAQ:WHWK

$4.20 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.20 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Xilio Therapeutics NASDAQ:XLO

$9.13 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.16 +0.03 (+0.38%)

As of 09/18/2026 04:10 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, CGEN, WHWK, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, CGEN, WHWK, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, CGEN, WHWK, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, CGEN, WHWK, and TARA Company Descriptions

Compugen NASDAQ:CGEN

Protara Therapeutics NASDAQ:TARA

Whitehawk Therapeutics NASDAQ:WHWK

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, CGEN, WHWK, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, CGEN, WHWK, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, CGEN, WHWK, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, CGEN, WHWK, and TARA Company Descriptions

Compugen NASDAQ:CGEN

Protara Therapeutics NASDAQ:TARA

Whitehawk Therapeutics NASDAQ:WHWK

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools